In this regard, a very recent study by Shi and colleagues [239] demonstrated that rapamycin-induced mTOR pathway inhibition in 5XFAD mice significantly compromised microglia Aβ plaque clearance, corroborating the notion that rapamycin use in AD patients should be carefully analyzed [240]. This evidence concerns the gene MTOR and Alzheimer disease.